High Levels of Toxic Chemicals Found in Disposable Puff E-Cigarettes

Aug.03.2022
High Levels of Toxic Chemicals Found in Disposable Puff E-Cigarettes
One-time use Puff e-cigarettes contain high levels of unknown chemicals and synthetic coolants that are toxic to human cells.

A picture of a disposable puff electronic cigarette from Talbot Lab at the University of California, Riverside. Electronic cigarettes (EC) contain nicotine, solvents, and flavored chemicals, and are particularly popular among young people. In 2020, the US Food and Drug Administration (FDA) banned flavored EC pods based on cartridges, but this ban did not extend to "disposable" flavored EC products, such as Puff EC. Unfortunately, the chemical composition and toxicity of the liquid in Puff ECs is largely unknown.


Researchers from the University of California Riverside and Portland State University have examined 16 disposable Puff devices to determine their flavor chemicals, synthetic cooling agents, and nicotine concentrations. One of the synthetic cooling agents tested is WS-23 which provides a cooling sensation.


A team used gas chromatography and mass spectrometry to identify 126 flavor chemicals in Puff EC liquid and tested their toxicity on human bronchial epithelial cells. They reported in the journal Toxicology and Chemistry that the chemical content in single-use Puff EC was high and had cytotoxicity or toxicity to living cells.


Our data supports the need to regulate the flavoring chemicals and synthetic cooling agents in Puff EC to limit their potentially harmful effects on health," said Esther Omaiye, a former graduate student in the Environmental Toxicology Graduate Program and first author of the research paper. "The levels of nicotine, flavoring chemicals, and synthetic cooling agents in Puff EC are higher than those found in other consumer products, raising concerns about the safety of Puff products.


Omaiye, a postdoctoral researcher in the Prue Talbot laboratory, stated that one of the areas of regulatory concern related to e-cigarettes is the continuous development of novel chemicals in e-liquids.


For many years, we have been aware that EC design has been continuously evolving," said Talbot, the professor of cell biology leading the research team.


Recently, it has been discovered that chemicals used in e-cigarette liquids are changing. These changes are often made to make e-cigarette products more appealing to teenagers or to avoid regulation by the FDA, such as using synthetic nicotine instead of tobacco-derived nicotine to avoid FDA restrictions.


According to Talbot, the synthetic cooling agent WS-23, developed for use in shaving cream, is now included in EC liquids, but there is little information available about its inhalation toxicity.


Our work indicates that the concentration of WS-23 used in Puff ECs is sufficient to have negative long-term health effects," she said.


Other findings of the study include:


The EC in Puff contains a much higher concentration of synthetic cooling agents and flavor chemicals than JUUL EC.


Despite the unknown risks of inhaling, EC manufacturers are increasing the use and concentration of synthetic cooling agents, which is appealing to young users.


This article is compiled from third-party information and is intended only for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truth or accuracy of its contents. The compilation of this article is solely for industry exchange and research purposes.


Due to limitations in translation abilities, the compiled article may not fully express or accurately reflect the original text. Please refer to the original text for accuracy.


Regarding any domestic, Hong Kong, Macao, Taiwan, or international related statements and positions, 2FIRSTS fully aligns with the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
FDA Authorizes JUUL2, Cites Adult Switching Amid Efforts to Speed PMTA Reviews
The FDA authorized the JUUL2 device and tobacco- and menthol-flavored pods on Aug. 28, bringing the number of authorized e-cigarette products to 48. The agency highlighted complete switching among adult smokers, with six-week switching rates reaching 28.4%–49.3% for the menthol pod. The decision comes as FDA works to speed PMTA reviews, reduce application backlogs and expand authorized e-cigarette and nicotine-pouch products while maintaining enforcement priorities for unauthorized products.
Regulations
Aug.29
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.
Regulations
Oct.09
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23